Skip to content

Study on rational application of antiinfective drugs for severe acute lower respiratory tract infections guided by rapid molecular pathogen diagnosis

Study on rational application of antiinfective drugs for severe acute lower respiratory tract infections guided by rapid molecular pathogen diagnosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057010
Enrollment
Unknown
Registered
2022-02-26
Start date
2022-02-26
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe pneumonia

Interventions

intervention group:conventional pathogen detection test+point of care molecular test
control group :conventional pathogen detection test

Sponsors

China-Japan Friend Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Duration of onset <=7 days; 3. Oxygen saturation <93% or oxygen partial pressure <60mmHg without oxygen inhalation, or oxygenation index.300mmHg under oxygen inhalation; 4. The patient met the diagnostic criteria for community-acquired pneumonia, hospital-acquired pneumonia or ventilator-associated pneumonia; Diagnostic criteria for community-acquired pneumonia: the diagnostic criteria of ''Chinese Adult Guidelines for Diagnosis and Treatment of Community-acquired Pneumonia (2016 Edition)'' were met; Diagnostic criteria for hospital-acquired pneumonia: Meet the diagnostic criteria of ''Guidelines for the Diagnosis and Treatment of hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Chinese Adults (2018 Edition)''; 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant patients; 2. Patients enrolled in this study within 90 days; 3. Patients with active tuberculosis; 4. Immunosuppressed patients: (1) Neutrophil deficiency (peripheral blood neutrophil count =20mg/ day (or equivalent dose of other hormones) for more than 30 days at onset; (5) CD4 cell count of peripheral blood T cell subsets <200/mm^3 during HIV infection; (6) Complement deficiency and immunoglobulin deficiency.

Design outcomes

Primary

MeasureTime frame
De-escalation rate of anti-infective therapy;

Countries

China

Contacts

Public ContactCao Bin
caobin_ben@163.com+86 10 84206264

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026